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ABSTRACT BODY: 
Abstract Body: The transcription factor CCATT/enhancer binding protein alpha (C/EBP-α) is known to have an
important regulatory role in the maintenance of normal hepatocyte function and response to injury. We developed a
small activating RNA (saRNA) that was demonstrated to significantly up-regulate C/EBP-α expression in primary
hepatocytes. This saRNA was subsequently encapsulated in an anionic liposome as a development candidate for
clinical use (MTL-CEBPA). Liver failure was induced in Sprague Dawley rats by twice weekly i.p. injection of CCl4 for
a duration of 8 weeks. For a further 2 weeks of the CCl4 regiment, animals were treated by twice weekly i.v. injection
of MTL-CEBPA via tail vein at 0.3mg/kg, 1mg/kg and 3mg/kg.
 
We demonstrate reversal and near normalisation of clinically relevant parameters following all treatment doses of
MTL-CEBPA including, at 3mg/kg, bilirubin (64% decrease), circulating alanine and aspartate aminotransferase (59%
and 62% decrease respectively) and prothrombin time (19% decrease). We also observed a significant increase in
serum albumin and total protein as well as a significant decrease in alkaline phosphatase and gamma-glutamyl-
transpeptidase. Liver hydroxyproline significantly decreased in a dose-dependent manner in addition to a significant
increase in body weight with no associated toxicity.
 
Here we present a novel development candidate, MTL-CEBPA, that safely up-regulates C/EBP-α, as a potential
treatment for liver failure in vivo. Clinical studies with MTL-CEBPA are expected to begin in early 2016.
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